A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

The advent of immune checkpoint‐inhibitors (CPI) has transformed treatment for several cancer types. This review was performed to assess the rate of adverse events (AEs) associated with the use of CPI, alone or in combinations. A review of AEs reporting quality was also performed. All publications o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer Jg. 145; H. 3; S. 639 - 648
Hauptverfasser:	Arnaud‐Coffin, Patrick, Maillet, Denis, Gan, Hui K., Stelmes, Jean‐Jacques, You, Benoit, Dalle, Stephane, Péron, Julien
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 01.08.2019
Schlagworte:	adverse event Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents, Immunological - adverse effects B7-H1 Antigen - antagonists & inhibitors Cancer Chemotherapy Clinical trials CTLA-4 Antigen - antagonists & inhibitors Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - etiology Humans Immune checkpoint inhibitors immune toxicity Immunotherapy Medical research Patients Programmed Cell Death 1 Receptor - antagonists & inhibitors quality control Randomized Controlled Trials as Topic systematic review adverse event immune checkpoint inhibitors quality control systematic review immune toxicity
ISSN:	0020-7136, 1097-0215, 1097-0215
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!